Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.
Saved in:
| Title: | Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol. |
|---|---|
| Authors: | van der Ploeg P; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Hendrikse CS; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Thijs AM; Department of Internal Medicine and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands., Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands., Smedts HP; Department of Obstetrics and Gynaecology, Amphia Hospital, Breda, the Netherlands., Vos MC; Department of Obstetrics and Gynaecology, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands., Jalving M; Department of Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands., Lok CA; Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Boere IA; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., van Ham MA; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, the Netherlands., Ottevanger PB; Department of Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands., Westermann AM; Department of Oncology, Amsterdam University Medical Centre, Amsterdam, the Netherlands., Mom CH; Department of Obstetrics and Gynaecology, Amsterdam University Medical Centre, Amsterdam, the Netherlands., Lalisang RI; Department of Medical Oncology, Maastricht University Medical Centre +, Maastricht, the Netherlands., Lambrechts S; Department of Obstetrics and Gynaecology, Maastricht University Medical Centre +, Maastricht, the Netherlands., Bekkers RL; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Piek JM; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands. |
| Source: | Heliyon [Heliyon] 2023 Dec 01; Vol. 10 (1), pp. e23170. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38187310 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22van+der+Ploeg+P%22">van der Ploeg P</searchLink>; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Hendrikse+CS%22">Hendrikse CS</searchLink>; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Thijs+AM%22">Thijs AM</searchLink>; Department of Internal Medicine and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Westgeest+HM%22">Westgeest HM</searchLink>; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Smedts+HP%22">Smedts HP</searchLink>; Department of Obstetrics and Gynaecology, Amphia Hospital, Breda, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Vos+MC%22">Vos MC</searchLink>; Department of Obstetrics and Gynaecology, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Jalving+M%22">Jalving M</searchLink>; Department of Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Lok+CA%22">Lok CA</searchLink>; Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Boere+IA%22">Boere IA</searchLink>; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Ham+MA%22">van Ham MA</searchLink>; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Ottevanger+PB%22">Ottevanger PB</searchLink>; Department of Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Westermann+AM%22">Westermann AM</searchLink>; Department of Oncology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Mom+CH%22">Mom CH</searchLink>; Department of Obstetrics and Gynaecology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Lalisang+RI%22">Lalisang RI</searchLink>; Department of Medical Oncology, Maastricht University Medical Centre +, Maastricht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Lambrechts+S%22">Lambrechts S</searchLink>; Department of Obstetrics and Gynaecology, Maastricht University Medical Centre +, Maastricht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Bekkers+RL%22">Bekkers RL</searchLink>; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Piek+JM%22">Piek JM</searchLink>; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101672560%22">Heliyon</searchLink> [Heliyon] 2023 Dec 01; Vol. 10 (1), pp. e23170. <i>Date of Electronic Publication: </i>2023 Dec 01 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101672560 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2405-8440 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224058440%22">24058440 </searchLink><i>NLM ISO Abbreviation: </i>Heliyon <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38187310 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.heliyon.2023.e23170 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e23170 Titles: – TitleFull: Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: van der Ploeg P – PersonEntity: Name: NameFull: Hendrikse CS – PersonEntity: Name: NameFull: Thijs AM – PersonEntity: Name: NameFull: Westgeest HM – PersonEntity: Name: NameFull: Smedts HP – PersonEntity: Name: NameFull: Vos MC – PersonEntity: Name: NameFull: Jalving M – PersonEntity: Name: NameFull: Lok CA – PersonEntity: Name: NameFull: Boere IA – PersonEntity: Name: NameFull: van Ham MA – PersonEntity: Name: NameFull: Ottevanger PB – PersonEntity: Name: NameFull: Westermann AM – PersonEntity: Name: NameFull: Mom CH – PersonEntity: Name: NameFull: Lalisang RI – PersonEntity: Name: NameFull: Lambrechts S – PersonEntity: Name: NameFull: Bekkers RL – PersonEntity: Name: NameFull: Piek JM IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2023 Dec 01 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 2405-8440 Numbering: – Type: volume Value: 10 – Type: issue Value: 1 Titles: – TitleFull: Heliyon Type: main |
| ResultId | 1 |
